Penelope Drake

Company: Catalent

Job title: Head, R&D

Seminars:

Catalent’s SMARTag® Technology: Differentiated Solutions for Optimal ADC 11:15 am

• Demonstrating how SMARTag is a clinicalstage ADC technology featuring sitespecific conjugation with multiple linker and warhead options • 6 CRs and 2 PRs among 22 patients were achieved by TRPH-222, a CD22-targeted SMARTag conjugate, in the dose-escalation stage of a Phase 1 trial for R/R B-cell lymphoma • Highlighting how new linkers are being…Read more

day: Track B - Day 1 - AM